Alprostadil
Caverject, Edex, Muse, Prostin (alprostadil) is a small molecule pharmaceutical. Alprostadil was first approved as Prostin vr pediatric on 1982-01-01. It is used to treat aortic arch syndromes, aortic coarctation, hypoplastic left heart syndrome, patent ductus arteriosus, and pulmonary hypertension amongst others in the USA. The pharmaceutical is active against prostaglandin E2 receptor EP1 subtype and prostaglandin E2 receptor EP2 subtype. In addition, it is known to target cation channel sperm-associated protein 3, prostacyclin receptor, prostaglandin D2 receptor, cation channel sperm-associated protein 4, cation channel sperm-associated protein 2, cation channel sperm-associated protein 1, prostaglandin E2 receptor EP4 subtype, and prostaglandin E2 receptor EP3 subtype.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
respiratory tract diseases | D012140 |
urogenital diseases | D000091642 |
cardiovascular diseases | D002318 |
hereditary congenital and neonatal diseases and abnormalities | D009358 |
Trade Name
FDA
EMA
Caverject, Edex, Muse, Prostin (generic drugs available since 1998-01-20)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alprostadil
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
EDEX | Auxilium Pharmaceuticals | N-020649 RX | 1997-06-12 | 6 products, RLD, RS |
MUSE | Mylan | N-020700 RX | 1996-11-19 | 3 products, RLD, RS |
PROSTIN VR PEDIATRIC | Mylan | N-018484 RX | 1982-01-01 | 1 products, RLD, RS |
CAVERJECT | Mylan | N-020379 RX | 1995-07-06 | 3 products, RLD, RS |
CAVERJECT IMPULSE | Mylan | N-021212 RX | 2002-06-11 | 2 products |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
alprostadil | ANDA | 2020-02-29 |
caverject | New Drug Application | 2023-03-24 |
edex | New Drug Application | 2018-08-22 |
prostin | New Drug Application | 2022-10-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
aortic arch syndromes | — | D001015 | — |
aortic coarctation | EFO_1001267 | D001017 | Q25.1 |
hypoplastic left heart syndrome | — | D018636 | Q23.4 |
patent ductus arteriosus | HP_0001643 | D004374 | Q25.0 |
pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
pulmonary valve stenosis | EFO_1001138 | D011666 | — |
tetralogy of fallot | HP_0001636 | D013771 | Q21.3 |
tricuspid atresia | — | D018785 | — |
vasculogenic impotence | EFO_1001234 | D018783 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01E: Other cardiac preparations in atc
— C01EA: Prostaglandin cardiac therapy preparations
— C01EA01: Alprostadil
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BE: Drugs used in erectile dysfunction
— G04BE01: Alprostadil
HCPCS
Code | Description |
---|---|
J0270 | Injection, alprostadil, 1.25 mcg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
J0275 | Alprostadil urethral suppository (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Eczema | D004485 | HP_0000964 | L30.9 | — | — | 4 | — | — | 4 |
Hand dermatoses | D006229 | — | — | 3 | — | — | 3 | ||
Male breast neoplasms | D018567 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatic insufficiency | D048550 | 1 | 1 | — | — | 1 | 2 | ||
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 1 | 2 |
Kaposi sarcoma | D012514 | C46 | — | 1 | — | — | 1 | 2 | |
Lichen planus | D008010 | L43 | — | 1 | — | — | — | 1 | |
Cutaneous lupus erythematosus | D008178 | EFO_0003834 | L93.1 | — | 1 | — | — | — | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ALPROSTADIL |
INN | alprostadil |
Description | Prostaglandin E1 is a prostaglandins E. It has a role as a platelet aggregation inhibitor, a vasodilator agent, an anticoagulant and a human metabolite. It is a conjugate acid of a prostaglandin E1(1-). |
Classification | Small molecule |
Drug class | vasodilators (undefined group); prostaglandins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O |
Identifiers
PDB | — |
CAS-ID | 745-65-3 |
RxCUI | 598 |
ChEMBL ID | CHEMBL495 |
ChEBI ID | 15544 |
PubChem CID | 5280723 |
DrugBank | DB00770 |
UNII ID | F5TD010360 (ChemIDplus, GSRS) |
Target
Agency Approved
PTGER1
PTGER1
PTGER2
PTGER2
Organism
Homo sapiens
Gene name
PTGER1
Gene synonyms
NCBI Gene ID
Protein name
prostaglandin E2 receptor EP1 subtype
Protein synonyms
PGE receptor, EP1 subtype, PGE2 receptor EP1 subtype, prostaglandin E receptor 1 (subtype EP1), 42kD, prostaglandin E receptor 1 (subtype EP1), 42kDa, prostaglandin E receptor 1, subtype EP1, Prostanoid EP1 receptor
Uniprot ID
Mouse ortholog
Ptger1 (19216)
prostaglandin E2 receptor EP1 subtype (P35375)
Alternate
CATSPER3
CATSPER3
PTGIR
PTGIR
PTGDR
PTGDR
CATSPER4
CATSPER4
CATSPER2
CATSPER2
CATSPER1
CATSPER1
PTGER4
PTGER4
PTGER3
PTGER3
Organism
Homo sapiens
Gene name
CATSPER3
Gene synonyms
NCBI Gene ID
Protein name
cation channel sperm-associated protein 3
Protein synonyms
Ca(v)-like protein, calcium channel repeat containing 1, One-repeat calcium channel-like protein, putative ion channel CatSper3
Uniprot ID
Mouse ortholog
Catsper3 (76856)
cation channel sperm-associated protein 3 (Q9D5T9)
Variants
Clinical Variant
No data
Financial
Edex - Auxilium Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,338 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alprostadil, Prostin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
63 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more